Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.
Michael F CrutchlowJohn S PalczaKate M MostollerChantal D MahonApril M BarbourMichael C MarcosYang XuElaine WatkinsLinda MorrowMarcus HompeschPublished in: Diabetes, obesity & metabolism (2017)
Based on comparative assessment in both T1D and healthy subjects, it can be concluded that the PK and PD properties of MK-1293 are highly similar to those of Lantus. (ClinicalTrials.gov: NCT02059174).